These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 17455910)

  • 1. Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells.
    Reigan P; Colucci MA; Siegel D; Chilloux A; Moody CJ; Ross D
    Biochemistry; 2007 May; 46(20):5941-50. PubMed ID: 17455910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo.
    Dehn DL; Siegel D; Zafar KS; Reigan P; Swann E; Moody CJ; Ross D
    Mol Cancer Ther; 2006 Jul; 5(7):1702-9. PubMed ID: 16891456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity.
    Colucci MA; Reigan P; Siegel D; Chilloux A; Ross D; Moody CJ
    J Med Chem; 2007 Nov; 50(23):5780-9. PubMed ID: 17944451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of NAD(P)H:quinone oxidoreductase I (NQO1) inhibition by mitomycin C in vitro and in vivo.
    Gustafson DL; Siegel D; Rastatter JC; Merz AL; Parpal JC; Kepa JK; Ross D; Long ME
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1079-86. PubMed ID: 12649308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical, cytotoxic, and genotoxic effects of ES936, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, in cellular systems.
    Dehn DL; Siegel D; Swann E; Moody CJ; Ross D
    Mol Pharmacol; 2003 Sep; 64(3):714-20. PubMed ID: 12920209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indolequinone antitumour agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase.
    Newsome JJ; Swann E; Hassani M; Bray KC; Slawin AM; Beall HD; Moody CJ
    Org Biomol Chem; 2007 May; 5(10):1629-40. PubMed ID: 17571194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
    Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
    Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches.
    Winski SL; Faig M; Bianchet MA; Siegel D; Swann E; Fung K; Duncan MW; Moody CJ; Amzel LM; Ross D
    Biochemistry; 2001 Dec; 40(50):15135-42. PubMed ID: 11735396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity.
    Beall HD; Winski S; Swann E; Hudnott AR; Cotterill AS; O'Sullivan N; Green SJ; Bien R; Siegel D; Ross D; Moody CJ
    J Med Chem; 1998 Nov; 41(24):4755-66. PubMed ID: 9822546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation.
    Xu S; Yao H; Pei L; Hu M; Li D; Qiu Y; Wang G; Wu L; Yao H; Zhu Z; Xu J
    Eur J Med Chem; 2017 May; 132():310-321. PubMed ID: 28395199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ES936 stimulates DNA synthesis in HeLa cells independently on NAD(P)H:quinone oxidoreductase 1 inhibition, through a mechanism involving p38 MAPK.
    González-Aragón D; Alcaín FJ; Ariza J; Jódar L; Barbarroja N; López-Pedrera C; Villalba JM
    Chem Biol Interact; 2010 Jul; 186(2):174-83. PubMed ID: 20433816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger.
    Siegel D; Gustafson DL; Dehn DL; Han JY; Boonchoong P; Berliner LJ; Ross D
    Mol Pharmacol; 2004 May; 65(5):1238-47. PubMed ID: 15102952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential.
    Colucci MA; Moody CJ; Couch GD
    Org Biomol Chem; 2008 Feb; 6(4):637-56. PubMed ID: 18264564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.
    Han Y; Shen H; Carr BI; Wipf P; Lazo JS; Pan SS
    J Pharmacol Exp Ther; 2004 Apr; 309(1):64-70. PubMed ID: 14718602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indolequinone inhibitors of NRH:quinone oxidoreductase 2. Characterization of the mechanism of inhibition in both cell-free and cellular systems.
    Yan C; Dufour M; Siegel D; Reigan P; Gomez J; Shieh B; Moody CJ; Ross D
    Biochemistry; 2011 Aug; 50(31):6678-88. PubMed ID: 21718050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent activity of indolequinones against human pancreatic cancer: identification of thioredoxin reductase as a potential target.
    Yan C; Shieh B; Reigan P; Zhang Z; Colucci MA; Chilloux A; Newsome JJ; Siegel D; Chan D; Moody CJ; Ross D
    Mol Pharmacol; 2009 Jul; 76(1):163-72. PubMed ID: 19364812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lavendamycin antitumor agents: structure-based design, synthesis, and NAD(P)H:quinone oxidoreductase 1 (NQO1) model validation with molecular docking and biological studies.
    Hassani M; Cai W; Koelsch KH; Holley DC; Rose AS; Olang F; Lineswala JP; Holloway WG; Gerdes JM; Behforouz M; Beall HD
    J Med Chem; 2008 Jun; 51(11):3104-15. PubMed ID: 18457384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methoxylation of resveratrol: effects on induction of NAD(P)H quinone-oxidoreductase 1 (NQO1) activity and growth inhibitory properties.
    Zhang W; Go ML
    Bioorg Med Chem Lett; 2011 Feb; 21(3):1032-5. PubMed ID: 21215623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dicumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism.
    Cullen JJ; Hinkhouse MM; Grady M; Gaut AW; Liu J; Zhang YP; Weydert CJ; Domann FE; Oberley LW
    Cancer Res; 2003 Sep; 63(17):5513-20. PubMed ID: 14500388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.
    Siegel D; Shieh B; Yan C; Kepa JK; Ross D
    J Pharmacol Exp Ther; 2011 Mar; 336(3):874-80. PubMed ID: 21156818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.